Teva and Biolojic enter therapeutic antibody development deal

Teva Pharmaceutical has signed a licence agreement with Biolojic Design for the development of BD9 to treat atopic dermatitis and asthma.

Related Posts

Chong Kun Dang Pharmaceutical gets grant for injectable...

Mar 30, 2024

Opinion: The complicated connections between weight los...

Feb 19, 2024

BioNTech shelves oral mRNA vaccine plans with Matinas

May 12, 2023